April 12, 2019

Sagetis Biotech today announced that in light of promising in-vivo results obtained, Duchenne Parent Project España has awarded Dr. Salvador Borrós and his team at Sagetis Biotech a one year extension to the signed grant to evaluate the coating of adeno-associated viruses (AAV) in order to increase their efficacy as a gene therapy strategy for Duchenne muscular dystrophy (DMD). 

The ongoing experiments with Adeno-associated vir...

March 29, 2019

March 29th, 2019 — Sagetis Biotech, S.L., today announced that it granted an exclusive license to research, develop, use, manufacture, and commercialize its polymeric coating technology (Viroshield) to aratinga.bio TNP.  The terms of that license agreement (financial terms not disclosed), gives aratinga.bio TNP worldwide rights to further develop the encapsulation technology for any retroviral-based applications and any plasmi...

December 3, 2018

Barcelona, Dec 3, 2018 - Sagetis Biotech is pleased to announce that Sagetis’ Chief Executive Officer, Eduard Diviu and R&D Head, Dr. Anna Cascante, will be attending Annual Oncolytic Virotherapy Summit in Boston (USA) from the 4th - 6th December 2018. Additionally, Dr. Anna Cascante will also give a presentation titled “Viroshield™: An Innovative Polymeric Coating Technology to Enable Systemic Delivery of Oncolytic Viruses” o...

February 2, 2018

The approval represents one further step in the uphill battle against pancreatic cancer.

Barcelona, February 2, 2018 - We are pleased to share the recent approval by the FDA of Lutathera® for the treatment of gastroenteropancreatic tumors, including pancreatic neuroendocrine tumors (PNETs), that express somatostatin receptors. PNETs make up about 6 percent of all pancreatic cancer diagnoses. In the held Phase III clinical trial...

December 22, 2017

Barcelona, December 22 2017 – Sagetis Biotech today announced that Duchenne Parent Project España awarded Dr. Salvador Borrós and his team at Sagetis Biotech a grant to evaluate the coating of adeno-associated viruses (AAV) in order to increase their efficacy as a gene therapy strategy for Duchenne muscular dystrophy (DMD). 

Duchenne Parent Project España, a nonprofit organization dedicated to the fight to end Duchenne muscular...

Please reload

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy